Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

(2017) Bo Ahrén et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

(2017) Christopher Sorli et al.   Lancet Diabetes & Endocrinology

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

(2017) Vanita R Aroda et al.   Lancet Diabetes & Endocrinology

Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study

(2016)   DIABETES CARE

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Effect of Bariatric Surgery on Diabetic Retinopathy: Good, Bad, or Both?

(2016) Dora M. Gorman et al.   Diabetes & Metabolism Journal

Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel

(2015) Christoph Kapitza et al.   JOURNAL OF CLINICAL PHARMACOLOGY

12. Management of Diabetes in Pregnancy

(2014)   DIABETES CARE

The impact of improved glycaemic control with GLP-1 receptor agonist therapy on diabetic retinopathy

(2014) Lakshminarayanan Varadhan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Global Prevalence and Major Risk Factors of Diabetic Retinopathy

(2012) J. W. Y. Yau et al.   DIABETES CARE

GLP-1 agonist treatment: Implications for diabetic retinopathy screening

(2011) Lakshminarayanan Varadhan et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

(2009) J. Rosenstock et al.   DIABETOLOGIA